Literature DB >> 15161649

alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease.

Nigel J Cairns1, Victoria Zhukareva, Kunihiro Uryu, Bin Zhang, Eileen Bigio, Ian R A Mackenzie, Marla Gearing, Charles Duyckaerts, Hideaki Yokoo, Yoichi Nakazato, Evelyn Jaros, Robert H Perry, Virginia M-Y Lee, John Q Trojanowski.   

Abstract

Neuronal intermediate filament (IF) inclusion disease (NIFID) is a novel neurological disease of early onset with a variable clinical phenotype including frontotemporal dementia, pyramidal, and extrapyramidal signs. Pathologically, in affected areas, there is neuronal loss, astrocytosis, and neuronal intracytoplasmic aggregates of abnormal neuronal IFs that contain neither tau nor alpha-synuclein. Thus, to characterize the neuronal IF protein profile of inclusions in NIFID, immunohistochemistry (IHC) was performed on 10 cases of NIFID, four normal aged controls (NL), and two cases of Alzheimer's disease (AD) using a panel of anti-neuronal IF proteins. Immunoelectron microscopy was performed on selected cases and frozen tissue from the frontal lobe of four cases was used for biochemical studies including sequential extractions and Western blotting. Based on these studies, we report here for the first time that alpha-internexin, a neuronal IF protein, is present within the inclusions of NIFID as are all three neurofilament subunits: heavy, medium, and light. Thus, all class IV neuronal IF proteins are present within the pathological inclusions of this disease. Biochemistry revealed that IF aggregates were soluble in sodium dodecyl sulfate (SDS) and no post-translational modification was detected when compared with Alzheimer's disease or aged control brains. Hence, we conclude that NIFID is characterized by the pathological cytoplasmic aggregation of all class IV neuronal IF proteins in brain. The discovery of alpha-internexin in the cytoplasmic inclusions implicates novel mechanisms of pathogenesis in NIFID and other neurological diseases with pathological accumulations of IFs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161649      PMCID: PMC1615782          DOI: 10.1016/s0002-9440(10)63773-x

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

Review 1.  From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.

Authors:  M Goedert; M G Spillantini; L C Serpell; J Berriman; M J Smith; R Jakes; R A Crowther
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-02-28       Impact factor: 6.237

2.  Purification of paired helical filament tau and normal tau from human brain tissue.

Authors:  V M Lee; J Wang; J Q Trojanowski
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

3.  Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia.

Authors:  V Zhukareva; V Vogelsberg-Ragaglia; V M Van Deerlin; J Bruce; T Shuck; M Grossman; C M Clark; S E Arnold; E Masliah; D Galasko; J Q Trojanowski; V M Lee
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

Review 4.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 5.  Update on the neuropathological diagnosis of frontotemporal dementias.

Authors:  J Q Trojanowski; D Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

6.  Phosphorylation state of the native high-molecular-weight neurofilament subunit protein from cervical spinal cord in sporadic amyotrophic lateral sclerosis.

Authors:  M J Strong; W L Strong; H Jaffe; B Traggert; M M Sopper; H C Pant
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

7.  Neurofilament-rich intraneuronal inclusions exacerbate neurodegenerative sequelae of brain trauma in NFH/LacZ transgenic mice.

Authors:  J E Galvin; M Nakamura; T K McIntosh; K E Saatman; D Sampathu; R Raghupathi; V M Lee; J Q Trojanowski
Journal:  Exp Neurol       Date:  2000-09       Impact factor: 5.330

8.  Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions.

Authors:  Nigel J Cairns; Robert H Perry; Evelyn Jaros; David Burn; Ian G McKeith; James S Lowe; Janice Holton; Martin N Rossor; Kari Skullerud; Charles Duyckaerts; Felix F Cruz-Sanchez; Peter L Lantos
Journal:  Neurosci Lett       Date:  2003-05-08       Impact factor: 3.046

9.  Neuropathologic variation in frontotemporal dementia due to the intronic tau 10(+16) mutation.

Authors:  P L Lantos; N J Cairns; M N Khan; A King; T Revesz; J C Janssen; H Morris; M N Rossor
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

Review 10.  Neurofilaments and neurological disease.

Authors:  Ammar Al-Chalabi; Christopher C J Miller
Journal:  Bioessays       Date:  2003-04       Impact factor: 4.345

View more
  47 in total

1.  alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases.

Authors:  Nigel J Cairns; Kunihiro Uryu; Eileen H Bigio; Ian R A Mackenzie; Marla Gearing; Charles Duyckaerts; Hideaki Yokoo; Yoichi Nakazato; Evelyn Jaros; Robert H Perry; Steven E Arnold; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2004-05-28       Impact factor: 17.088

2.  Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons.

Authors:  Aidong Yuan; Takahiro Sasaki; Asok Kumar; Corrinne M Peterhoff; Mala V Rao; Ronald K Liem; Jean-Pierre Julien; Ralph A Nixon
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

3.  Neuronal intranuclear inclusions are ultrastructurally and immunologically distinct from cytoplasmic inclusions of neuronal intermediate filament inclusion disease.

Authors:  Sabrina Mosaheb; Julian R Thorpe; Lida Hashemzadeh-Bonehi; Eileen H Bigio; Marla Gearing; Nigel J Cairns
Journal:  Acta Neuropathol       Date:  2005-07-16       Impact factor: 17.088

Review 4.  Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration.

Authors:  Rodolphe Perrot; Raphael Berges; Arnaud Bocquet; Joel Eyer
Journal:  Mol Neurobiol       Date:  2008-07-23       Impact factor: 5.590

5.  Neuropathological changes in ten cases of neuronal intermediate filament inclusion disease (NIFID): a study using alpha-internexin immunohistochemistry and principal components analysis (PCA).

Authors:  R A Armstrong; E Kerty; K Skullerud; N J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

6.  Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease.

Authors:  Manuela Neumann; Sigrun Roeber; Hans A Kretzschmar; Rosa Rademakers; Matt Baker; Ian R A Mackenzie
Journal:  Acta Neuropathol       Date:  2009-08-09       Impact factor: 17.088

7.  FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.

Authors:  Tristan Page; Michael A Gitcho; Sabrina Mosaheb; Deborah Carter; Sumi Chakraverty; Robert H Perry; Eileen H Bigio; Marla Gearing; Isidre Ferrer; Alison M Goate; Nigel J Cairns; Julian R Thorpe
Journal:  J Mol Neurosci       Date:  2011-05-21       Impact factor: 3.444

8.  A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.

Authors:  Masataka Nakamura; Kevin F Bieniek; Wen-Lang Lin; Neill R Graff-Radford; Melissa E Murray; Monica Castanedes-Casey; Pamela Desaro; Matthew C Baker; Nicola J Rutherford; Janice Robertson; Rosa Rademakers; Dennis W Dickson; Kevin B Boylan
Journal:  Acta Neuropathol       Date:  2015-04-28       Impact factor: 17.088

9.  Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis.

Authors:  Richard A Armstrong; William Ellis; Ronald L Hamilton; Ian R A Mackenzie; John Hedreen; Marla Gearing; Thomas Montine; Jean-Paul Vonsattel; Elizabeth Head; Andrew P Lieberman; Nigel J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2009-12-10       Impact factor: 3.575

Review 10.  Selective functional, regional, and neuronal vulnerability in frontotemporal dementia.

Authors:  William W Seeley
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.